BioMarin Pharmaceutical Inc (BMRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

BioMarin Pharmaceutical Inc (BMRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH27812D
  • |
  • Pages: 107
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Kyndrisa (drisapersen), Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product category consists of multiple clinical and preclinical offerings. The company operates through its manufacturing facilities in Novato, California. It conducts its buisiness operations in the US, Europe, Latin America, the Middle East, and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc (BMRN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

BioMarin Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 12

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deal Details 15

Venture Financing 15

ProSensa Raises USD 30 Million In Series C Financing Round 15

Partnerships 17

Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 17

Licensing Agreements 18

Avrobio Enters into Licensing Agreement with BioMarin Pharma 18

Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 19

BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 21

BioMarin Enters Into Licensing Agreement With Repligen For Histone Deacetylase Inhibitor Portfolio 22

Shire Human Genetic Enters into Licensing Agreement with Biomarin Pharma 23

Catalyst Pharma Amends Licensing Agreement with BioMarin Pharmaceutical 24

BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program 26

Equity Offering 28

BioMarin Pharma Raises USD720 Million in Public Offering of Shares 28

BioMarin Pharma Raises USD911.5 Million in Public Offering of Shares 29

BioMarin Pharma Completes Public Offering Of Shares For USD 119.3 Million 30

BioMarin Completes Public Offering Of Common Stock For USD 236 Million 31

Debt Offering 32

BioMarin Pharma Completes Underwriters Exercise of Over-Allotment Option of 0.599% Notes Due 2024 for USD45 Million 32

BioMarin Pharma Completes Public Offering Of Notes Due 2020 For USD 375 Million 33

BioMarin Pharma Completes Public Offering Of Notes Due 2018 For USD 375 Million 35

Asset Transactions 37

Medivation Acquires Rights to Talazoparib from BioMarin Pharma 37

Acquisition 38

Sanofi May Acquire BioMarin Pharma 38

Roche May Acquire BioMarin Pharma 39

BioMarin Pharmaceutical (BioMarin Pharma) Acquires 100% stake in Prosensa for USD751.5 Million 40

Roche Rumored to Acquire BioMarin Pharma for USD13.5 Billion 42

BioMarin Pharma Acquires Zacharon Pharma For USD9.7 Million 43

GlaxoSmithKline Plans To Acquire BioMarin Pharma 44

BioMarin Pharmaceutical Inc-Key Competitors 45

BioMarin Pharmaceutical Inc-Key Employees 46

BioMarin Pharmaceutical Inc-Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Joint Venture 48

Recent Developments 49

Financial Announcements 49

Oct 25, 2018: BioMarin Pharmaceutical reports third quarter 2018 results 49

Aug 02, 2018: BioMarin announces second quarter 2018 results 52

Apr 25, 2018: BioMarin Announces First Quarter 2018 Financial Results 55

Feb 22, 2018: BioMarin Reports Fourth Quarter 2017 Financial Results 58

Oct 26, 2017: BioMarin Announces Third Quarter 2017 Financial Results 61

Aug 02, 2017: BioMarin Announces Second Quarter 2017 Financial Results 65

May 04, 2017: BioMarin Announces First Quarter 2017 Financial Results 67

Feb 23, 2017: BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results 69

Jan 10, 2017: BioMarin Transfers Duchenne Natural History Database to CureDuchenne To Improve Knowledge of Duchenne Patients and Improve Clinical Outcomes 71

Corporate Communications 72

Oct 03, 2017: BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors 72

Product News 73

Dec 14, 2017: Gene therapy success could lead to cure for haemophilia 73

12/11/2017: BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting 74

12/06/2017: BioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition 76

09/06/2017: BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome at 13th International Congress of Inborn Errors of Metabolism 2017 77

09/05/2017: BioMarin To Present Data On ICV BMN 250 At 13th International Congress of Inborn Errors of Metabolism 2017 79

07/11/2017: BioMarins Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within Normal Range for over One Year 81

06/16/2017: BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress 83

05/22/2018: BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress 84

05/17/2018: BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress 86

05/15/2018: BioMarin Announces First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy in Severe Hemophilia A Patients with Pre-existing AAV5 Antibodies 88

04/27/2017: FDA approves first treatment for a form of Batten disease 89

04/21/2017: New medicine for rare neurodegenerative disorder in children 91

04/21/2017: BioMarin Receives Positive CHMP Opinion in Europe for Brineura (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children 92

03/21/2018: BioMarin's Gene Therapy Manufacturing Facility Recognized with Industry Award 94

02/07/2018: BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at WORLDSymposium 2018 95

01/08/2017: BioMarin to Provide Update to Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A at 35th Annual J.P. Morgan Healthcare Conference 97

Product Approvals 99

Feb 01, 2017: BioMarin Receives Access to Priority Medicines Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophilia A 99

Clinical Trials 100

Jan 23, 2018: Local researcher leads breakthrough for haemophilia patients 100

Dec 19, 2017: BioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A 101

Dec 09, 2017: BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology Annual Meeting Concurrent with NEJM Publication 102

Oct 26, 2017: FDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A 104

Aug 02, 2017: BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies 105

Appendix 107

Methodology 107

About GlobalData 107

Contact Us 107

Disclaimer 107

List of Figures

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

BioMarin Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 12

List of Tables

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

BioMarin Pharmaceutical Inc, Deals By Therapy Area, 2012 to YTD 2018 10

BioMarin Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 12

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

ProSensa Raises USD 30 Million In Series C Financing Round 15

Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 17

Avrobio Enters into Licensing Agreement with BioMarin Pharma 18

Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 19

BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 21

BioMarin Enters Into Licensing Agreement With Repligen For Histone Deacetylase Inhibitor Portfolio 22

Shire Human Genetic Enters into Licensing Agreement with Biomarin Pharma 23

Catalyst Pharma Amends Licensing Agreement with BioMarin Pharmaceutical 24

BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program 26

BioMarin Pharma Raises USD720 Million in Public Offering of Shares 28

BioMarin Pharma Raises USD911.5 Million in Public Offering of Shares 29

BioMarin Pharma Completes Public Offering Of Shares For USD 119.3 Million 30

BioMarin Completes Public Offering Of Common Stock For USD 236 Million 31

BioMarin Pharma Completes Underwriters Exercise of Over-Allotment Option of 0.599% Notes Due 2024 for USD45 Million 32

BioMarin Pharma Completes Public Offering Of Notes Due 2020 For USD 375 Million 33

BioMarin Pharma Completes Public Offering Of Notes Due 2018 For USD 375 Million 35

Medivation Acquires Rights to Talazoparib from BioMarin Pharma 37

Sanofi May Acquire BioMarin Pharma 38

Roche May Acquire BioMarin Pharma 39

BioMarin Pharmaceutical (BioMarin Pharma) Acquires 100% stake in Prosensa for USD751.5 Million 40

Roche Rumored to Acquire BioMarin Pharma for USD13.5 Billion 42

BioMarin Pharma Acquires Zacharon Pharma For USD9.7 Million 43

GlaxoSmithKline Plans To Acquire BioMarin Pharma 44

BioMarin Pharmaceutical Inc, Key Competitors 45

BioMarin Pharmaceutical Inc, Key Employees 46

BioMarin Pharmaceutical Inc, Subsidiaries 47

BioMarin Pharmaceutical Inc, Joint Venture 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

BioMarin Pharmaceutical Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17845
Site License
USD 500 INR 35690
Corporate User License
USD 750 INR 53535

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com